Clarion News

Perspectives from the 2018 ASH Annual Meeting

SHARE:

The 2018 Annual Meeting of the American Society of Hematology (ASH) took place in San Diego on December 1-4. As the world’s largest hematology congress, ASH highlighted extraordinary advances in cutting edge therapeutics for both blood cancers and hematologic rare diseases. Below, Clarion presents a summary of important findings and insights emerging from the meeting.

Key takeaways

  • Hematologic cancers—Novel targeted therapies, combinations, and immunotherapies are poised to redefine standards of care in AML, MDS, multiple myeloma, non-Hodgkin lymphoma, and CLL
  • Hematologic rare diseases—New disease-modifying targeted therapies are emerging for sickle cell disease (SCD), while the gene therapy field strives to realize its potential in SCD, hemophilia B & A, and other genetic disorders

2018 ASH Meeting Summary and Clarion Perspectives

Is Clarion the right place to advance your career?

Find out more about joining Clarion’s team of innovation advisors.

A life sciences strategy and organizational consultancy that collaborates with its clients to envision, craft and enable growth through innovation and leadership.